Skip to main content
OpenTrials
Completed

NCT Number: NCT03938298

The ESTxENDS Trial: Pulmonary Function Substudy

--> This is a substudy of the main ESTxENDS trial (NCT03589989). Pulmonary function outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989.

Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer, e-cigarette or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. The inhaled ENDS aerosol appears safe in laboratory conditions, its long-term effects on pulmonary function remains unknown. This study will therefore investigate the impact of ENDS on lung function in smokers, who attempt to quit using ENDS compared with smokers, receiving only smoking cessation counseling with nicotine replacement therapy (NRT).

Multiple breath washout (MBW) is an established technique for assessment of peripheral airway function in pediatrics and its use is emerging in adult medicine, as it offers a better sensitivity to assess small airway disease before large airway involvement can be detected using conventional pulmonary function tests (PFT - spirometry, body plethysmography and diffusing capacity test). Preliminary evidence from limited studies suggest MBW parameters (LCI, Scond, Sacin) can be impaired in smokers with normal lung function and improve after smoking abstinence.

Primary objective of this substudy is to assess changes in LCI from baseline to 6 months post target quit date (TQD) in cigarette smokers randomized to the intervention group compared to the control group.

For the main ESTxENDS trial (NCT03589989), cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standard of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. Participants in the control group will receive only standard of care. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Pneumology, Bern, Switzerland

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent as documented by signature
  • Persons aged 18 or older
  • Currently smoking 5 or more cigarettes a day for at least 12 months
  • Willing to try to quit smoking within the next 3 months
  • Persons providing a valid phone number, a valid email address and/or a valid postal address.

Exclusion criteria

  • Known hypersensitivity or allergy to contents of the e-liquid
  • Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study
  • Persons having used ENDS or tobacco heating systems regularly in the 3 months preceding the baseline visit
  • Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit
  • Persons who cannot attend the 6-month follow-up visit for any reason
  • Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

Treatment and study plan

ENDS (vaporizer/e-cig) and smoking cessation counseling

Other

Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.

PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy.

Smoking cessation counseling

Other

Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.

PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy.

Primary outcomes

  1. Changes in Lung Clearance Index (LCI)

    Time frame: Change from baseline to 6 months post quit date

    Measured by multiple breath washout (MBW) of a tracer gas (N2). LCI is defined as the cumulative expired volume/functional residual capacity (CEV/FRC) at 5% and 2.5% tracer gas concentration in the exhaled breath. An LCI with a z-score < + 1.645 (upper limit of normal according to Singer F et al, PLoS One. 2012;7(4):e36083) is considered normal.

Secondary outcomes

  1. Lung Clearance Index (LCI)

    Time frame: 6 months post quit date

    Measured by multiple breath washout (MBW) of a tracer gas (N2). LCI is defined as the cumulative expired volume/functional residual capacity (CEV/FRC) at 5% and 2.5% tracer gas concentration in the exhaled breath. An LCI with a z-score < + 1.645 (upper limit of normal according to Singer F et al, PLoS One. 2012;7(4):e36083) is considered normal.

  2. Changes in Scond and Sacin

    Time frame: Change from baseline to 6 months post quit date

    Measured by multiple breath washout (MBW). MBW assesses ventilation of the peripheral airways.

  3. Scond and Sacin

    Time frame: 6 months post quit date

    Measured by multiple breath washout (MBW). MBW assesses ventilation of the peripheral airways.

  4. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 6 months post quit date

    Measured by spirometry. Spirometry is a conventional pulmonary function test measuring airflow.

  5. Changes in Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Change from baseline to 6 months post quit date

    Measured by spirometry. Spirometry is a conventional pulmonary function test measuring airflow.

  6. Forced Expiratory Volume in 1 Second/Functional Vital Capacity Ratio (FEV1/FVC)

    Time frame: 6 months post quit date

    Measured by spirometry. Spirometry is a conventional pulmonary function test measuring airflow.

  7. Changes in Forced Expiratory Volume in 1 Second/Functional Vital Capacity Ratio (FEV1/FVC)

    Time frame: Change from baseline to 6 months post quit date

    Measured by spirometry. Spirometry is a conventional pulmonary function test measuring airflow.

  8. Total Lung Capacity (TLC)

    Time frame: 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  9. Changes in Total Lung Capacity (TLC)

    Time frame: Change from baseline to 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  10. Residual Volume (RV)

    Time frame: 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  11. Changes in Residual Volume (RV)

    Time frame: Change from baseline to 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  12. Residual Volume to Total Lung Capacity (RV/TLC)

    Time frame: 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  13. Changes in Residual Volume to Total Lung Capacity (RV/TLC)

    Time frame: Change from baseline to 6 months post quit date

    Measured by body plethysmography. Body plethysmography is a conventional pulmonary function test measuring lung volumes.

  14. Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)

    Time frame: 6 months post quit date

    Measured by diffusing capacity test.

  15. Changes in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)

    Time frame: Change from baseline to 6 months post quit date

    Measured by diffusing capacity test.

  16. Fraction of exhaled nitric oxide (FeNO)

    Time frame: 6 months post quit date

    Measured by the levels of nitric oxide in the exhaled breath.

  17. Changes in Fraction of exhaled nitric oxide (FeNO)

    Time frame: Change from baseline to 6 months post quit date

    Measured by the levels of nitric oxide in the exhaled breath.

Sponsors and collaborators

Lead sponsor

University of Bern

Other

Collaborators

  • Bernese Lung League
  • Insel Gruppe AG, University Hospital Bern
  • Swiss National Science Foundation

Registry information

Official study title

Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS): Pulmonary Function Substudy (PulmENDS)

Acronym: PulmENDS

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
May 6, 2019
Registry last updated
Nov 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.